Loading...

Fennec Pharmaceuticals Inc.

FRX.TOTSX
HealthcareBiotechnology
CA$11.25
CA$0.00(0.00%)

Fennec Pharmaceuticals Inc. FRX.TO Peers

See (FRX.TO) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
FRX.TOCA$11.25N/A310.7M-15.41-CA$0.73N/A
BLU.TOCA$19.48-0.10%2.5B-20.29-CA$0.96N/A
MMED.NECA$14.90+9.48%1.1B-4.50-CA$3.31N/A
DRUG.CNCA$35.25-7.33%249.7M-185.53-CA$0.19N/A
CYBN.NECA$10.91-1.27%229.4M-2.20-CA$4.96N/A
EPRX.TOCA$5.34-1.29%191.4M-5.13-CA$1.04N/A
MSCL.TOCA$0.65+1.54%114.4M2.71CA$0.24N/A
GLAB.CNCA$1.02+10.91%76.4M-20.40-CA$0.05N/A
MSET.CNCA$0.74-1.33%75M-12.33-CA$0.06N/A
MDNA.TOCA$0.95-6.86%74.3M-2.64-CA$0.36N/A
Showing 1 to 10 of 59 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

FRX.TO vs BLU.TO Comparison

FRX.TO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, FRX.TO stands at 310.7M. In comparison, BLU.TO has a market cap of 2.5B. Regarding current trading prices, FRX.TO is priced at CA$11.25, while BLU.TO trades at CA$19.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

FRX.TO currently has a P/E ratio of -15.41, whereas BLU.TO's P/E ratio is -20.29. In terms of profitability, FRX.TO's ROE is +0.19%, compared to BLU.TO's ROE of -0.22%. Regarding short-term risk, FRX.TO is less volatile compared to BLU.TO. This indicates potentially lower risk in terms of short-term price fluctuations for FRX.TO.

Stock Price Comparison

Loading...

Frequently Asked Questions